Leukemia & lymphoma/Leukemia and lymphoma · 2003 · 58 citations · 19 references
MedicineHematologyOncologyChemotherapyMedical OncologyNeuro-oncologyCentral Nervous System LymphomaHigh-dose ChemotherapyNeuro-oncology Clinical TrialsRelapsed DiseaseHigh-dose Methotrexate TherapyLymphoma Central Nervous System TherapyLymphoma ChemotherapyMultiagent ChemotherapyPrimary Central Nervous System Lymphoma RadiotherapyPrimary Central Nervous System Lymphoma TherapySecond-line Chemotherapy
The treatment of primary central nervous system lymphoma (PCNSL) has centered around high-dose methotrexate and radiotherapy (RT). Methotrexate administered intra-arterially (IA) with blood-brain barrier disruption (BBBD) and without RT, has been a highly effective treatment with a 5 year survival of 42% without cognitive loss. The purpose of this analysis is to determine responses for patients with relapsed PCNSL treated with second line IA carboplatin-based chemotherapy with BBBD. Between February 1991 and April 2000, 37 relapsed PCNSL patients, most who failed front line therapy with methotrexate based chemotherapy, were treated at Oregon Health & Science University (OHSU) and Hadassah Hebrew University Hospital (HHUH) with IA carboplatin-based chemotherapy with BBBD. Nine patients had prior RT. The mean age was 57.5 years, and all but 1 patient were treated within 8 months after relapse. The median time for survival from first IA carboplatin/BBBD treatment was 6.8 months;however, 7 out of 37 patients survived > or = 27 months. Nine patients had radiographic complete response (CR), 4 patients had radiographic partial response (PR), 12 had stable disease (SD), 10 had progressive disease (PD), and 2 were non-evaluable. The median time to failure for patients with CR and PR was 9.1 months. One long-term survivor is alive at 91.0 months from first carboplatin/BBBD treatment. In conclusion, we show that relapsed PCNSL has shown sensitivity to second line IA carboplatin-based chemotherapy with BBBD. We have developed a new protocol using i.v. rituximab prior to BBBD with IA carboplatin, i.v. cyclophosphamide and i.v. etoposide phosphate. The long-term program goal is to consolidate dose-intensive chemotherapy with monoclonal antibody directed radiation. Because patients with recurrent PCNSL commonly continue to relapse even after obtaining a complete response to enhanced chemotherapy treatment, patients w ho complete or fail the above carboplatin/BBBD treatment regimen will be offered consolidation with radioimmunotherapy using zevalin (Ibritumomab tiuxetan), IDEC-2B8 conjugated with yttrium-90 (90Y).
19
Horder, William Harnett · BMJ · 1941 · 1.3K citations · Full text
Long-term survival in primary CNS lymphoma.
Lauren E. Abrey, Lisa M. DeAngelis, Joachim Yahalom · Journal of Clinical Oncology · 1998 · 578 citations
Medicine, Oncology, Pharmacotherapy +15
Nancy D. Doolittle, Michael E. Miner, Walter A. Hall et al. · Cancer · 2000 · 396 citations
Medicine, Neurosurgery, Oncology +16